Register for email alerts and news feeds:
This journal | BMJ Group
rss
Published Online First: 15 January 2009. doi:10.1136/jcp.2008.055343
Journal of Clinical Pathology 2009;62:414-421
Copyright © 2009 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

REVIEW

How molecular pathology is changing and will change the therapeutics of patients with follicular cell-derived thyroid cancer

J Pinto Couto1,3, H Prazeres1,2,3, P Castro1, J Lima1, V Máximo1, P Soares1,3, M Sobrinho-Simões1,3,4

1 IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto) Porto, Portugal
2 Molecular Pathology Laboratory, Portuguese Institute of Oncology, Coimbra, Portugal
3 Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal
4 Department of Pathology, Hospital São João, Porto, Portugal

Dr M Sobrinho-Simões, IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), R. Roberto Frias s/n, 4200-265 Porto, Portugal; ssimoes{at}ipatimup.pt

Well-differentiated thyroid carcinomas comprise two well-defined histological types: papillary and follicular (PTCs and FTCs, respectively). Despite being derived from the same cell (thyroid follicular cell), these two types of tumour accumulate distinct genetic abnormalities during progression. The molecular pathology of thyroid cancer is now better understood because of our ability to identify RET/PTC rearrangements and BRAF mutations in the aetiopathogenesis of the large majority of PTCs and the high prevalence of RAS mutations and PAX8/PPAR{gamma} rearrangements in follicular patterned carcinomas (FTCs and follicular variant of PTCs). This review summarises most of the molecular alterations currently used as targets for new biological treatments and looks at some of the changes that are already occurring or may occur in the treatment of patients with thyroid cancer. For simplicity, the review is divided up according to the major genetic alterations identified in well-differentiated thyroid carcinomas (RET/PTC rearrangements, BRAF mutations, RAS mutations and mitochondrial DNA deletions and mutations) and their respective treatments.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs